Found 81 results
Author Title [ Type(Asc)] Year
Filters: Author is William H. Bisson  [Clear All Filters]
Journal Article
W. H. Bisson, Editorial: computational chemogenomics in drug design and discovery., Current topics in medicinal chemistry, vol. 12, p. 1867, 2012.
W. H. Bisson, Drug repurposing in chemical genomics: can we learn from the past to improve the future?, Current topics in medicinal chemistry, vol. 12, pp. 1883–1888, 2012.
T. D. Hubbard, Murray, I. A., Bisson, W. H., Sullivan, A. P., Sebastian, A., Perry, G. H., Jablonski, N. G., and Perdew, G. H., Divergent Ah receptor ligand selectivity during hominin evolution., Mol Biol Evol, 2016.
K. Badri Narayanan, Ali, M., Barclay, B. J., Cheng, Q. Shawn, D’Abronzo, L., Dornetshuber-Fleiss, R., Ghosh, P. M., Guzman, M. J. Gonzalez, Lee, T. - J., Leung, P. Sing, and Bisson, W. H., Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death, Carcinogenesis, vol. 36, pp. S89–S110, 2015.
A. Carnero, Blanco-Aparicio, C., Kondoh, H., Lleonart, M. E., Martinez-Leal, J. Fernando, Mondello, C., A Scovassi, I., Bisson, W. H., Amedei, A., Roy, R., and Bisson, W. H., Disruptive chemicals, senescence and immortality, Carcinogenesis, vol. 36, pp. S19–S37, 2015.
A. Carnero, Blanco-Aparicio, C., Kondoh, H., Lleonart, M. E., Martinez-Leal, J. Fernando, Mondello, C., A Scovassi, I., Bisson, W. H., Amedei, A., Roy, R., and Bisson, W. H., Disruptive chemicals, senescence and immortality, Carcinogenesis, vol. 36, pp. S19–S37, 2015.
W. H. Bisson, Cheltsov, A. V., Bruey-Sedano, N., Lin, B., Chen, J., Goldberger, N., May, L. T., Christopoulos, A., Dalton, J. T., Sexton, P. M., and , Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs, Proceedings of the National Academy of Sciences, vol. 104, pp. 11927–11932, 2007.
S. K. Joshi, Bisson, W. H., Qian, K., Huang, A., Watanabe-Smith, K., Tyner, J. W., Davare, M. Ashok, McWeeney, S. K., Tognon, C. E., and Druker, B. J., Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in LeukemiaDisclosures, Blood, vol. 134, no. Supplement_1, pp. 1256 - 1256, 2019.
T. Wang, Bisson, W. H., Mäser, P., Scapozza, L., and Picard, D., Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologues enable the structure-based discovery of pathogen-selective inhibitors, Journal of medicinal chemistry, vol. 57, pp. 2524–2535, 2014.
M. Ceccon, Mologni, L., Bisson, W. H., Scapozza, L., and Gambacorti-Passerini, C., Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors, Molecular Cancer Research, vol. 11, pp. 122–132, 2013.
L. Yang, Broderick, D., Campbell, Y., Gombart, A. F., Stevens, J. F., Jiang, Y., Hsu, V. L., Bisson, W. H., and Maier, C. S., Conformational Modulation of the Farnesoid X Receptor by Prenylflavonoids: Insights from Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS), Fluorescence Titration and Molecular Docking Studies., Biochim Biophys Acta, 2016.
G. G. Sharma, Cortinovis, D., Agustoni, F., Arosio, G., Villa, M., Cordani, N., Bidoli, P., Bisson, W. H., Pagni, F., Piazza, R., Gambacorti-Passerini, C., and Mologni, L., A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib, Journal of Thoracic Oncology, vol. 14, no. 11, pp. e257 - e259, 2019.
H. Kim, Banerjee, N., Ivanov, I., Pfent, C. M., Prudhomme, K. R., Bisson, W. H., Dashwood, R. H., Talcott, S. T., and Mertens-Talcott, S. U., Comparison of anti-inflammatory mechanisms of mango ( Mangifera Indica L.) and pomegranate ( Punica Granatum L.) in a preclinical model of colitis, Molecular Nutrition & Food Research, p. n/a - n/a, 2016.
L. R. Zarour, Anand, S., Billingsley, K. G., Bisson, W. H., Cercek, A., Clarke, M. F., Coussens, L. M., Gast, C. E., Geltzeiler, C. B., Hansen, L., Kelley, K. A., Lopez, C. D., Rana, S. R., Ruhl, R., V Tsikitis, L., Vaccaro, G. M., Wong, M. H., and Mayo, S. C., Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions., Cell Mol Gastroenterol Hepatol, vol. 3, no. 2, pp. 163-173, 2017.
J. Kravchenko, Corsini, E., Williams, M. A., Decker, W., Manjili, M. H., Otsuki, T., Singh, N., Al-Mulla, F., Al-Temaimi, R., Amedei, A., and Bisson, W. H., Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions, Carcinogenesis, p. bgv033, 2015.
S. A. S. Langie, Koppen, G., Desaulniers, D., Al-Mulla, F., Al-Temaimi, R., Amedei, A., Azqueta, A., Bisson, W. H., Brown, D., Brunborg, G., and , Causes of genome instability: the effect of low dose chemical exposures in modern society, Carcinogenesis, vol. 36, pp. S61–S88, 2015.
W. H. Bisson, Zhang, Z., Welsh, K., Huang, J. - W., Ryan, J., Reed, J. C., and Pellecchia, M., Binding Properties of the C-terminal Domain of VIAF, Chemical biology & drug design, vol. 72, pp. 331–336, 2008.
Z. Hu, Brooks, S. A., Dormoy, V., Hsu, C. - W., Hsu, H. - Y., Lin, L. - T., Massfelder, T., W Rathmell, K., Xia, M., Al-Mulla, F., and Bisson, W. H., Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis, Carcinogenesis, vol. 36, pp. S184–S202, 2015.
W. H. Goodson, Lowe, L., Carpenter, D. O., Gilbertson, M., Ali, A. Manaf, Salsamendi, A. Lopez de C., Lasfar, A., Carnero, A., Azqueta, A., Amedei, A., and Bisson, W. H., Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead, Carcinogenesis, vol. 36, pp. S254–S296, 2015.
E. F. O'Donnell, Koch, D. C., Bisson, W. H., Jang, H. S., and Kolluri, S., The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells, Cell death & disease, vol. 5, p. e1038, 2014.
E. F. O'Donnell, Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R. L., and Kolluri, S. Kumar, The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor., PLoS One, vol. 5, no. 10, 2010.
E. F. O'Donnell, Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R. L., and Kolluri, S., The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor, PLoS ONE, vol. 5, no. 10, p. e13128, 2010.
E. F. O'Donnell, Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R., and , The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor, PLoS One, vol. 5, p. e13128, 2010.
D. C. Koch, Jang, H. S., O'Donnell, E. F., Punj, S., Kopparapu, P. R., Bisson, W. H., Kerkvliet, N. I., and Kolluri, S., Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1., Oncogene, 2015.
S. Sengupta, Bisson, W. H., Mathew, L. K., Kolluri, S., and Tanguay, R. L., Alternate glucocorticoid receptor ligand binding structures influence outcomes in an in vivo tissue regeneration model, Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, vol. 156, no. 2, pp. 121 - 129, 2012.

Pages